Background RubinsteineTaybi syndrome (RSTS) is a congenital neurodevelopmental disorder defined by postnatal growth deficiency, characteristic skeletal abnormalities and mental retardation and caused by mutations in the genes encoding for the transcriptional co-activators with intrinsic lysine acetyltransferase (KAT) activity CBP and p300. Previous studies have shown that neuronal histone acetylation is reduced in mouse models of RSTS. Methods The authors identified different mutations at the CREBBP locus and generated lymphoblastoid cell lines derived from nine patients with RSTS carrying distinct CREBBP mutations that illustrate different grades of the clinical severity in the spectrum of the syndrome. They next assessed whether histone acetylation levels were altered in these cell lines. Results The comparison of CREBBP-mutated RSTS cell lines with cell lines derived from patients with an unrelated mental retardation syndrome or healthy controls revealed significant deficits in histone acetylation, affecting primarily histone H2B and histone H2A. The most severe defects were observed in the lines carrying the whole deletion of the CREBBP gene and the truncating mutation, both leading to a haploinsufficiency state. Interestingly, this deficit was rescued by treatment with an inhibitor of histone deacetylases (HDACi). Conclusions The authors' results extend to humans the seminal observations in RSTS mouse models and point to histone acetylation defects, mainly involving H2B and H2A, as relevant molecular markers of the disease.
INTRODUCTION
RubinsteineTaybi syndrome (RSTS; Online Mendelian Inheritance in Man #180849, #613684) is a poorly understood autosomal-dominant disorder that affects one out of 125 000 newborns. 1 The disease is characterised by postnatal growth retardation, cognitive impairment, skeletal abnormalities and a high incidence of neoplasia. 2 3 Individuals with RSTS experience difficulty in planning and executing motor acts and have a short attention span and a low intelligence level with an average IQ of 50, although mental range can go from 25 to 80. 4 5 The distinctive anatomical features, including facial dysmorphisms, hypertelorism, prominent nose, malpositioned ears and especially broad thumbs and toes, are commonly used for diagnosis that can be confirmed by genetic screen. Two genes are currently known to be responsible for RSTS: CREBBP encoding for the cAMP response elementbinding protein (CREB)-binding protein (also known as CBP) and located at 16p13.3 6 and EP300 encoding for the E1A associated protein p300, highly homologous to CBP, and located at 22q13. 7 Frameshift, nonsense, splice site and missense point mutations in the CREBBP locus (in decreasing order of prevalence) are found in about 50% of RSTS cases, 6e18 whereas deletions of part or all of the CREBBP gene and flanking regions may account for an additional 5%e10% of the cases. 13 19 20 A few gene-disrupting translocations and inversions have been also reported. 6 19 21e25 EP300 mutations are comparatively rare. Only seven cases have been described so far in patients with a mild clinical presentation. 7 26e29 CBP and p300 are transcriptional co-activators with intrinsic lysine acetyltransferase activity 30 (KAT, previously referred to as histone acetyltransferase, 31 HAT) that act in different signal transduction pathways and are involved in the control of cell growth, cellular differentiation, DNA repair, apoptosis and tumour suppression. 32 33 They also play an important role in the development of the skeletal and central nervous systems. Although little is still known about the specific epigenetic modifications associated to this syndrome, as well as its relative significance in terms of transcriptional defects, the deficiency on KAT activity during development and in adulthood seems to be the most likely cause of RSTS symptoms.
Studies in mouse models of RSTS have provided valuable information on RSTS aetiology and revealed a critical role for CBP's KAT activity in cognitive processes. 34e38 These studies have shown that the loss or reduction of CBP is associated with reduced bulk levels of histone acetylation in the brain. In cbp +/À mice, the model that better reproduces the genetic alteration found in most patients with RSTS, the acetylation of histone H2B is particularly affected, 36 whereas in neurons of CBP conditional knockouts, all four histones are affected, but the deficit in acetylation is still stronger in the case of histones H2B and H2A.
39e41 No significant reduction of bulk histone acetylation was observed in the hippocampus of p300 hemizygous mice, which show very mild cognitive deficiencies, strengthening the correlation between reduced neuronal histone acetylation and cognitive impairments. 42 The main objective of this study is to investigate whether histone acetylation is also affected in patients with RSTS. Towards this end, we have selected a group of patients with RSTS who carry different molecular lesions of CREBBP and are therefore representative of the main types of causative mutations. We obtained lymphoblastoid cell lines from these patients and examined the consequences of the mutation in bulk histone acetylation. The results of these experiments extend our seminal findings in crebbp mutant mice and revealed that histone acetylation deficits are concomitant with cognitive impairments also in humans.
MATERIALS AND METHODS Patients
One hundred ten individuals clinically diagnosed as having RSTS were genetically tested for mutations of the CREBBP gene. This scan identified a cohort of CREBBP-positive patients with RSTS, consisting of 43 patients carrying heterozygous point mutations and 7 carrying deletions in one allele. Among these cases, we selected nine patients representative of the wide clinical variability of the syndrome and its allelic heterogeneity. They all show skeletal abnormalities with broad thumb or hallux and have typical facial features of RSTS with psychomotor and mental retardation ranging from mild to severe. Malformations and other signs of the disease were reported in some patients. See table 1 for additional details. The patients with Cornelia de Lange syndrome (CdLS) all carry heterozygous mutations in the NIPBL gene.
Molecular test of CREBBP mutation and bioinformatic analysis
As a first step in our study, we performed fluorescence in situ hybridisation (FISH) analysis to detect total or partial deletions in the CREBBP gene in those samples in which chromosome spreads could be set up. Then, we screened the coding region of the CREBBP gene by denaturing high-performance liquid chromatography (DHPLC) and direct sequencing. Bacterial artificial chromosome-FISH (BAC-FISH) on the genomic region harbouring CREBBP gene and DHPLC/DNA sequencing of all coding exons of CREBBP were performed as previously described. 12 20 Reverse transcriptase-PCR (RT-PCR) analysis of mutated alleles was also performed as previously described. 12 All the detected mutations were searched and confirmed in the corresponding cell lines. BAC clones for FISH analysis were selected according to Genome Browser (http://genome.ucsc.edu). PCR conditions for DHPLC screening were determined using the software Optimase Protocol Writer. ClustalW2 (http://www.ebi. ac.uk/Tools/clustalw2/index.html) was used to analyse the amino acidic sequence alignment of human CBP versus Drosophila, Caenorhabditis elegans and murine CBP, and versus human p300. PolyPhen (http://coot.embl.de/PolyPhen) was used for prediction of the possible effect of any amino acid substitution, and the Splice Site Prediction by Neural Network (http:// www.fruitfly.org/seq_tools/splice.htm) tool at the Berkeley Drosophila Genome Project was used to predict the consequences of mutations affecting putative splicing donor or acceptor sites.
Cell lines establishment, maintenance and treatment
Lymphoblastoid cell lines from all patients and healthy individuals were established by EpsteineBarr virus transformation of peripheral blood mononuclear cells, in collaboration with Galliera Genetic Bank (Istituto Galliera, Genoa, Italy). All cells were grown in RPMI 1640 media (Sigma, Saint Louis, MI, USA) supplemented with 2 mM L-glutamine, 10% fetal bovine serum (Invitrogen, Camarillo, CA, USA) and penicillin/streptomycin. In trichostatin A (TSA) experiments, cells were incubated for 2 h with vehicle (dimethyl sulfoxide (DMSO)) or 2 mM TSA in fresh media. This treatment did not affect cell viability in the time frame of our experiments.
Quantitative RT-PCR
Total cellular RNA isolation was performed using RNeasy kit (Qiagen Inc., Chatsworth, CA, USA). Reverse transcription was performed using RevertAid First Strand cDNA synthesis kit (Fermentas, St. Leon-Rot, Germany). Quantitative RT-PCR (qRT-PCR) was carried out on a ABI 7300 Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA) and amplified using SYBR GreenER qPCR reagent (Invitrogen). Each sample was assayed in duplicate and normalised using GAPDH levels. Primer sequences for amplification of CBP, p300 and GAPDH transcripts were designed using Primer Express Software V.2.0 (Applied Biosystems).
Quantitative western blotting
Western blot analyses were carried out as previously described. 43 The following home-made and commercial primary antibodies and dilutions were used: rabbit anti-histone H2B (1:10000) and mouse anti-histone H3 (1:10 000) (Abcam, Cambridge, UK), mouse anti b-actin (Sigma) (1:50 000); anti-acetylated histone H2A (AcH2A) (1:1000), anti-acetylated histone H2B (AcH2B) (1:10 000), anti-acetylated histone H3 (1:10 000) and anti-acetylated histone H4 (AcH4) (1:1000). 43 Secondary antibodies were anti-mouse HRP (1:10 000) and anti-rabbit HRP (1:10 000) (Sigma).
Fluorescent activated cell sorting (FACS) analysis
Cells (1e5310 6 cells) were fixed overnight in 70% ethanol solution at À208C, pelleted and washed twice with staining buffer (phosphate-buffered saline with 1% fetal bovine serum). A total of 1310 5 cells per condition were incubated with rabbit anti-acetyl histone H2B for 30 min at room temperature. Cells were washed and then stained with an Alexa Fluor 488-conjugated goat anti-rabbit antibody (Invitrogen) for 20 min at room temperature in the dark. Washes and staining steps were performed using staining buffer. Background staining was determined in negative cell lines and with matched fluorochrome-conjugated isotype controls. Cells were analysed on a FACSAria III flow cytometer (BD biosciences, Franklin Lakes, NJ, USA).
Statistical methods
Precise description of the statistical methods used in each experiment is presented in the text. In the graphs, error bars represent SEM.
RESULTS

Characterisation of novel CREBBP mutations and transcript analysis in peripheral blood and lymphoblastoid cell lines from patients with RSTS
To investigate the acetylation state of the chromatin of cells from patients with RSTS, we obtained lymphoblastoid cells lines from peripheral blood of patients of special interest based on their clinical features and/or the nature of their molecular pathogenetic lesions. These patients were selected from a large cohort of 110 patients diagnosed as having RSTS recruited from different Italian clinical units and screened for mutations in CREBBP. Among the 50 patients whose clinical diagnosis could be confirmed by molecular and/or FISH analysis of the CREBBP gene, nine were selected for further study through the generation of lymphoblastoid cell lines. This panel of patients with RSTS is representative of the different clinical manifestations of the syndrome, as detailed in table 1, and of the allelic heterogeneity at the CREBBP locus. The genetic lesions carried by the selected patients include a whole gene deletion and eight point 
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Medical complications Ocular problems Myopia, strabismus mutations: four missense, three splicing and a truncating mutation. Three out of these nine mutations have been previously described, 12 20 while the characterisation of the remaining six patients is presented here for the first time.
Missense mutations
All missense mutations were de novo as they were searched and excluded in the probands' parents and in 50 healthy individuals. Patient 46 (c.4627G/T, p.D1543T in exon 28) has been previously described, 12 while patients 84, 98 and 127 are carriers of novel missense mutations (c.5060C/T, p.S1687F in exon 30; c.2014G/C, p.L1338F in exon 24 and c.4444T/G, p.T1482D in exon 27, respectively). We checked whether the mutation found on the DNA could be detected at the RNA level and confirmed the presence of the aberrant transcript beside the normal one in all four cases. The comparative amino acid sequence analysis revealed that all the mutations affect amino acids that are highly conserved through evolution and in the figure 1A,B) . In particular, the mutation of patient 127 maps into the subdomain postulated to be the coenzyme A binding site (amino acids 1459e1541). The mutation carried by patient 46 has been confirmed also in the DNA isolated from the cheek and thigh where the patient developed the benign epithelial tumours pilomatrixomas.
Splicing mutations
Patient 20, previously described, 12 and the newly identified patients 99 and 114 carry different types of splice site mutations. The mutations found in patients 20 and 99 affect canonical splicing sites and lead to the activation of cryptic exonic splice sites, whereas the mutation of patients 114 affects a 'noncanonical' splicing site. In all cases, we investigated the aberrant CREBBP transcripts resulting from the missplicing. Patient 20 mutation, c.4728+1G/A, affecting the intervening sequence (IVS) 28 donor splice site has been found to generate a transcript skipping 104 bp of exon 28 through the activation of a cryptic exonic donor site: the frameshift produced by missplicing should lead to the incorporation of 38 anomalous amino acids. 12 The splice site mutation identified in patient 99 is a G/T substitution in the first base of IVS1 (85+1 G/T) arising de novo and yet unreported. Bioinformatic analysis of the patient cDNA predicted the presence of three different transcripts: the wildtype one that appears to be expressed at the highest levels and two longer transcripts. We sequenced the two aberrant transcripts characterised by the retention of different portions of IVS1 and found that the two transcripts originate from the activation of two of the predicted donor sites with a highest score after the canonical one ( figure 1C) . Translation of the two aberrant transcripts is hypothesised to generate the same truncated protein of 46 amino acids. Patient 114 carries the de novo mutation c.4485-7C/G affecting the nucleotide at position 7 of the consensus sequence in IVS25. According to Splice Site Prediction, this substitution leads to a decrease of the score of IVS25 acceptor site. cDNA analysis identified two aberrant transcripts, one skipping exon 26 and one skipping exons 25 and 26 ( figure 1D) , that keep the same frame and encode proteins lacking 49 and 87 aas, respectively.
Truncating mutation
Patient 75 carries a novel truncating mutation, c.2356delC in exon 13 leading to frameshift and predicting the truncated protein p.Q786RfsX20. RNA analysis evidenced the presence of both transcripts: the normal and the aberrant originated by the mutant allele.
Whole gene deletion
The deletion of patient 41 12 20 encompasses a 500 kb region beyond the 5 9 and 3 9 ends of the CREBBP gene.
B cells from these nine patients with RSTS were immortalised using EpsteineBarr virus. For comparison purposes, we also obtained lymphoblastoid cell lines from blood samples of three normal individuals and three children with CdLS, a mental retardation disorder molecularly unrelated to RSTS.
Expression of CREBBP and EP300 in cell lines from patients with RSTS
We examined by qRT-PCR whether the mutations into the CREBBP locus affected the level of CBP transcripts. These assays revealed that the cell lines derived from seven of the nine patients with RSTS showed the same level of CBP transcripts as the control lines derived from healthy individuals and patients with CdLS ( figure 2A ). Patient 41, who carries a complete deletion of a CREBBP allele, had half-level of mRNA. Patient 20, whose mutation produces an aberrant transcript lacking part of exon 28, 12 also showed a similar reduction of CBP transcript since one of the primers used for qRT-PCR mapped in the sequence missing in this patient. The absence of significant changes in the other lines indicates that despite the genomic mutations, the mutant or truncated transcripts are stable and have a similar transcription rate as the wild-type transcripts. This was the case even for the cell line derived from patient 75, who carries an early truncating mutation and likely produces untranslatable transcripts potentially prone to accelerated decay. We also tested whether CBP deficiency led to the upregulation of EP300 expression given the high homology between these two genes. P300-specific qRT-PCR assays in the 15 cell lines did not reveal any significant difference at the level of transcription, indicating that there is no compensation of CBP reduction through overexpression of p300 mRNA (figure 2B). Interestingly, our qRT-PCR analysis indicates that the level of CBP transcripts in these cells is almost one order of magnitude larger than for p300 transcripts ( figure 2C ).
Chromatin acetylation deficits in cell lines from patients with RSTS
We next obtained protein extracts from cultures in exponential growth for each cell line and assessed for histone acetylation deficits through western blotting using an array of antibodies raised against different Lys in the N-termini of histones H2A, Figure 2 CBP and p300 transcript levels in RubinsteineTaybi syndrome (RSTS) and control lymphoblastoid cell lines. AeB. mRNA levels for CREBBP (A) and EP300 (B), normalised to GAPDH mRNA levels, in the cell lines derived from patients with RSTS and control cell lines (non-RSTS). White squares () depict cell lines derived from healthy control individuals (CTRL), and white circles (B) represent cell lines established from patients with CdLS. The symbol legend for RSTS cell lines is at the bottom of the figure (see also figure 1B ). Symbols in the figure denote one cell line and represent the average of three to five individual measurements. Cell line from patient 41 carries a whole gene deletion of the CREBBP locus and shows a significant reduction of CBP transcripts compared to control cell lines and to CdLS-derived cell lines (*p<0.05, one-way analysis of variance followed by Tukey post hoc test). n¼3e5 samples per group. C. The graph shows relative abundance of CBP and p300 transcripts. Since the efficiency of the two qRT-PCR primer pairs is the same, this result indicates that CBP is much more highly expressed than p300 in the lymphoblastoid cell lines.
H2B, H3 and H4. The acetylation test revealed significant differences in the level of histone H2A and H2B between the cell lines derived from patients with RSTS (considered as a group) and either one of the two control groups (figure 3). In contrast, histones H3 and H4 showed levels of histone acetylation that did not differ from those observed in samples from healthy controls and patients with CdLS. Our experiments also revealed apparent differences between the different RSTS cell lines. Whereas line RSTS41 showed robust histone acetylation deficits affecting several histones, most lines showed more modest and specific deficits, and line RSTS99 was not distinguishable from the control lines (table 2) . In particular, we observed the biggest deficits in the lines derived from patients 41, 75, 127, 84 and 98.
Treatment with HDACi reverses the histone acetylation deficits of RSTS-derived cells
The acetylation of histones is regulated by the counteracting activity of KAT and histone deacetylase enzymes that respectively add or remove acetyl groups from histones. We next tested whether the treatment with an inhibitor of histone acetyltransferases (HDACi) reversed the hypoacetylation of histones. Towards this end, we selected the cell line showing the largest deficit, RSTS41, and treated the cultures either with the HDACi TSA or with the vehicle DMSO. Like previously reported for CBP-deficient mice, 36 40 western blotting analysis of protein extracts from cell cultures treated with TSA showed a level of bulk histone H2B acetylation higher than that observed in mutant and control cell lines treated with vehicle ( figure 4A ). To confirm the rescue of the acetylation deficit using an alternative technique, we used flow cytometry. Cells were fixed, permeabilised, stained with anti-AcH2B antibody and analysed in a FACSAria III cell sorter. We did not observe differences in the forward scatter/side scatter distribution between genotypes or treatments, indicating that TSA did not affect cell viability. This experiment confirmed the reduction of histone H2B acetylation in cells derived from patient 41 when compared to a control cell line and the reversal of the deficit upon treatment with TSA (figure 4BeC).
DISCUSSION
We reported here the identification of six new mutations in the CREBBP gene associated to RSTS, widening the spectrum of mutations associated to this disorder. In addition, we investigated the possible histone acetylation deficits in lymphoblastoid cell lines derived from nine patients carrying different types of mutation in the CREBBP gene including those carrying the novel mutations and three previously reported patients. 12 20 We observed deficits in histone acetylation in most of these cell lines that are similar to those observed in the brain of mice deficient in CBP activity, effectively translating seminal observations in mouse models of RSTS to humans.
The examination of the acetylation state of the four nucleosome histones in the nine cell lines generated from individuals with RSTS and the six lines from healthy individuals or mentally impaired individuals with a different pathology revealed consistent abnormalities. The acetylation assay of the four nucleosome histones shows a general reduction of bulk acetylation levels in patients with RSTS as compared to the controls, particularly for histone H2B and H2A. The worst deficit was observed in the cell line from patient 41 bearing a CBP null allele and showing severe mental retardation. Variable acetylation deficits were observed in patients that are carriers of missense and splicing mutations. The cells from patients 98, 75, 127 and 114 showed significant deficits affecting the acetylation state of more than one histone, whereas those from patients 20, 84 and 46 showed milder defects. Finally, the cells derived from patient 99 (which carry a splicing mutation that predicts a prematurely truncated protein) did not show any significant deficit, although we cannot exclude that, in the absence of apparent alterations at the bulk histone acetylation level, there were defects in specific genomic loci. Given the very limited impact of the splicing mutation in RSTS99 cells, we hypothesise that the splicing alteration in this patient may be partial. Although, in the most extreme examples, we observe certain correlation between cognitive impairments and epigenetic alterations in the cell lines, overall, it is difficult to correlate the severity of the molecular alterations and specific symptoms of the disease. In line with the limited effect of some of the mutations affecting the KAT domain in our analyses, two recent studies using primary murine embryonic fibroblasts from CBP/ p300 cre-deleted double knockout mice showed that mutant CBP proteins carrying missense mutations that disrupt the KAT domain, including mutations such as Q1500P, previously associated to RSTS, still retain significant KAT activity and their expression only results in a modest reduction in H3K18 acetylation when compared to wild-type CBP. 44 45 Although the role of CBP and p300 as KAT proteins has been investigated in animal models of the disease, this represents the first study on acetylation capability performed in human cell lines obtained from patients with RSTS who are carrier of different CREBBP genetic lesions. The lack to access to diseased neural tissue of patients with RSTS severely limits the translation of molecular observation in animal models to the clinic. The use of peripheral blood and derived immortalised cell lines can however provide some initial insight into the molecular aetiology of the disease till the generation of RSTS-specific induced pluripotent stem cells and their differentiation to neurons. 46 Thus, the detection of histone acetylation deficits in samples from patients with RSTS is of considerable value for understanding the molecular aetiology of this disorder. It has been suggested that histone acetylation/deacetylation in neurons play a critical role in memory, addiction, neurogenesis and other forms of neural plasticity. 47 48 As a consequence, some cognitive and physiological deficits observed in RSTS may not simply be due to defects originating during development, but may result from the continued requirement of normal levels of KAT activity throughout life. 34 Interestingly, the experiments with an HDACi in two RSTS cell lines showing significant deficits in the acetylation of histone H2B demonstrated a rescue of the defect, confirming the plasticity of the acetylation state and the possibility of modulating it, and paving the way to the idea of a therapeutic treatment of RSTS. Given the proven efficacy of HDACi, including TSA, in RSTS mouse models, 36 37 49 the confirmation of the existence of similar biochemical deficits in cell lines from patients and their reversal by HDACi open new therapeutic possibilities. There is great interest in the pharmaceutical industry for developing 'epi-drugs' suitable for treating brain diseases. 50 Various histone deacetylases, more specific and showing less noxious side effects than TSA, are currently being tested for the treatment of different forms of cancer and neurodegeneration. If the results of these clinical trials were positive and the new compounds show minimal side effects, it would be worthwhile to test their effectiveness also in the treatment of RSTS. 
